|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 178.75 USD | -1.94% |
|
-3.87% | +94.44% |
| 06-12 | AstraZeneca says Truqap combination approved in US for prostate cancer | AN |
| 06-12 | AstraZeneca Says FDA Approves Truqap Combination for PTEN-Deficient Prostate Cancer | MT |
"Total Return" performance includes dividend payments over the period, as if they were reinvested at 100%.
The annotated values (TR) are displayed with their "Total Return" performance (only if available).
End-of-day quotes
The annotated values (TR) are displayed with their "Total Return" performance (only if available).
End-of-day quotes
Compared values
| Sector | Change | 5-day change | YTD change | 1-year change | 5-year change | Capi. | ST | MT | LT | ||
|---|---|---|---|---|---|---|---|---|---|---|---|
| ASTRAZENECA PLC | Other Pharmaceuticals | -1.94% | -3.87% | +94.44% | +140.19% | +204.20% | 280B |
-
|
-
|
-
|
- Stock Market
- Stocks
- AZN Stock
- AZN Stock
- Charts AstraZeneca PLC
- Comparison Chart
Select your edition
All financial news and data tailored to specific country editions
